Ástralía - enska - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - isavuconazonium sulfate, quantity: 186.3 mg (equivalent: isavuconazole, qty 100 mg) - capsule - excipient ingredients: potassium acetate; gellan gum; iron oxide red; sodium lauryl sulfate; titanium dioxide; hypromellose; disodium edetate; magnesium citrate; microcrystalline cellulose; purified talc; colloidal anhydrous silica; stearic acid; propylene glycol; butan-1-ol; purified water; isopropyl alcohol; shellac; strong ammonia solution; ethanol absolute; iron oxide black; potassium hydroxide - cresemba is indicated in adults for the treatment of ? invasive aspergillosis ? mucormycosis in patients for whom amphotericin b is inappropriate (see section 4.4 special warnings and precautions for use and section 5.1 pharmacodynamic properties),consideration should be given to official guidance on the appropriate use of antifungal agents.

Nýja-Sjáland - enska - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - aluminium sulfate hydrate 37.28%{relative} equivalent to 20% w/v anhydrous;  ;   - topical gel - 20% w/v - active: aluminium sulfate hydrate 37.28%{relative} equivalent to 20% w/v anhydrous     excipient: colloidal silicon dioxide sls fragrance 380221 sodium laureth sulfate terics texapon water - minimises the pain, inflammation and itching associated with stings and bites of insects and plants, including ants, bees, wasps, mosquitoes, sandflies, sea lice, vines and nettles.

Belgía - enska - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

conforma sa-nv - aluminium sulfate 100 g/1 l - cutaneous solution - aluminium sulfate 0.14 mg/ml - other antiseptics and disinfectants

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - lamivudine, quantity: 300 mg; abacavir sulfate, quantity: 702.76 mg (equivalent: abacavir, qty 600 mg) - tablet, film coated - excipient ingredients: hypromellose; titanium dioxide; sunset yellow fcf aluminium lake; macrogol 8000; croscarmellose sodium; magnesium stearate; colloidal anhydrous silica; microcrystalline cellulose - abacavir and lamivudine combination tablets are a combination of two nucleoside analogues (abacavir and lamivudine). ,abacavir and lamivudine combination tablets are indicated in antiretroviral combination therapy for the treatment of human immunodeficiency virus (hiv) infection in adults and adolescents from 12 years of age.

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - abacavir sulfate,lamivudine -

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - morphine sulfate pentahydrate, quantity: 60 mg - tablet, modified release - excipient ingredients: hyetellose; magnesium stearate; purified talc; lactose monohydrate; hypromellose; povidone; titanium dioxide; sunset yellow fcf aluminium lake; macrogol 400 - for the management of severe pain where other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and the pain is opioid-responsive, and requires daily, continuous, long-term treatment. is not indicated for use in chronic non-cancer pain other than in exceptional circumstances. is not indicated as an as-needed (prn) analgesia.

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

mundipharma pty ltd - morphine sulfate pentahydrate, quantity: 20 mg - tablet, film coated - excipient ingredients: povidone; lactose; magnesium stearate; purified talc; pregelatinised maize starch; titanium dioxide; sunset yellow fcf aluminium lake; polyvinyl alcohol; macrogol 3350; erythrosine aluminium lake - treatment of chronic severe pain of cancer.

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - clopidogrel hydrogen sulfate, quantity: 391.5 mg (equivalent: clopidogrel, qty 300 mg) - tablet, film coated - excipient ingredients: hydrogenated castor oil; hyprolose; microcrystalline cellulose; mannitol; macrogol 6000; carnauba wax; titanium dioxide; lactose monohydrate; hypromellose; triacetin; iron oxide red - prevention of vascular ischaemia associated with atherothrombotic events (myocardial infarction, stroke and vascular death) in patients with a history of symptomatic atherosclerotic disease. acute coronary syndrome. plavix is indicated in combination with aspirin for patients with: unstable angina or non-st-elevation myocardial infarction in order to prevent early and long-term atherothrombotic events (myocardial infarction, stroke, vascular death or refractory ischaemia). plavix is indicated for the treatment of acute coronary syndrome whether or not patients undergo cardiac revascularisation (surgical or pci, with or without stent). st-segment elevation acute myocardial infarction in order to prevent atherothrombotic events. in this population, plavix has been shown to reduce the rate of death from any cause and the rate of a combined endpoint of death, re-infarction or stroke in medically treated patients eligible for thrombolytic therapy.

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - clopidogrel hydrogen sulfate, quantity: 97.875 mg (equivalent: clopidogrel, qty 75 mg); aspirin, quantity: 100 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; stearic acid; carnauba wax; hyprolose; colloidal anhydrous silica; maize starch; hydrogenated castor oil; macrogol 6000; mannitol; titanium dioxide; lactose monohydrate; hypromellose; triacetin; iron oxide red - duocover is a fixed-dose combination product intended as continuation of therapy in patients with acute coronary syndrome already initiated with separate clopidogrel and aspirin products: unstable angina or non-st-elevation myocardial infarction in order to prevent early and long-term atherothrombotic events (myocardial infarction, stroke, vascular death or refractory ischaemia). duocover is indicated for the treatment of acute coronary syndrome whether or not patients undergo cardiac revascularisation (surgical or pci, with or without stent). st-segment elevation acute myocardial infarction in order to prevent atherothrombotic events. in this population, duocover has been shown to reduce the rate of death from any cause and the rate of a combined endpoint of death, re-infarction or stroke in medically treated patients eligible for thrombolytic therapy.

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - clopidogrel hydrogen sulfate, quantity: 97.875 mg (equivalent: clopidogrel, qty 75 mg); aspirin, quantity: 100 mg - tablet, film coated - excipient ingredients: hyprolose; colloidal anhydrous silica; microcrystalline cellulose; maize starch; macrogol 6000; stearic acid; mannitol; carnauba wax; hydrogenated castor oil; titanium dioxide; lactose monohydrate; hypromellose; triacetin; iron oxide red - duoplidogrel is a fixed-dose combination product intended as continuation of therapy in patients with acute coronary syndrome already initiated with separate clopidogrel and aspirin products: unstable angina or non-st-elevation myocardial infarction in order to prevent early and long-term atherothrombotic events (myocardial infarction, stroke, vascular death or refractory ischaemia). duoplidogrel is indicated for the treatment of acute coronary syndrome whether or not patients undergo cardiac revascularisation (surgical or pci, with or without stent). st-segment elevation acute myocardial infarction in order to prevent atherothrombotic events. in this population, duoplidogrel has been shown to reduce the rate of death from any cause and the rate of a combined endpoint of death, re-infarction or stroke in medically treated patients eligible for thrombolytic therapy.